Article Text

Download PDFPDF
EMA suspends licence for ingenol mebutate (Picato)

Abstract

Overview of: Medicines and Healthcare products Regulatory Agency. Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Drug Safety Update 2020;13(7):1.

  • adherence
  • adverse effects
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.